Tuesday, April 18, 2023 10:11:23 AM
Recent SABS News
- SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors • GlobeNewswire Inc. • 05/06/2024 11:15:00 AM
- SAB Biotherapeutics Provides SAB-142 Trial Update • GlobeNewswire Inc. • 04/16/2024 11:15:00 AM
- SAB Biotherapeutics to Present at INNODIA Annual Meeting • GlobeNewswire Inc. • 04/08/2024 11:15:00 AM
- SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/04/2024 11:15:00 AM
- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/29/2024 11:15:00 AM
- SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment • GlobeNewswire Inc. • 03/25/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:30:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:55:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:45:19 PM
- SAB Biotherapeutics to Present at the BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/23/2024 01:00:00 PM
- SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 12:53:44 PM
- SAB Biotherapeutics Announces Executive Leadership Change • GlobeNewswire Inc. • 02/02/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:15:19 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/26/2024 09:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 10:00:09 PM
- SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 01/23/2024 10:58:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:21:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 02:00:08 PM
- SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split • GlobeNewswire Inc. • 01/02/2024 09:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/18/2023 02:34:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/08/2023 10:26:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/30/2023 10:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 12:40:46 PM
- SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes • GlobeNewswire Inc. • 11/29/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM